Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live sha256:949ff
    4/30/2026, 2:41:24 PM
    Content snapshot 
    {
  "nct_id": "NCT03887455",
  "phase": "phase_3",
  "status": "completed",
  "domain": "alzheimers",
  "indication": "Early Alzheimer's Disease",
  "intervention": "Lecanemab (anti-amyloid monoclonal)",
  "sponsor": "Eisai / Biogen",
  "n_enrolled": 1795,
  "primary_endpoint": "CDR-Sum of Boxes change from baseline at 18 months",
  "summary": "Anti-amyloid monoclonal that achieved 27% slowing on CDR-SB; led to traditional FDA approval July 2023. Defined the post-amyloid AD-disease-modifying era.",
  "metadata": {}
}